Latest Information Update: 05 Sep 2002
At a glance
- Originator XOMA
- Class Antifungals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 04 Nov 1999 New profile, split from Research programme: Mycoprex antifungal compounds - XOMA
- 07 Apr 1997 Preclinical development for Mycoses in USA (Unknown route)